J. David Enloe, Jr.
President and Chief Executive Officer
J. David Enloe brings over two decades of executive leadership experience in biotechnology, clinical drug development, and GMP manufacturing. Most recently, he served as president and chief executive officer of Ajinomoto Bio-Pharma Services, a global, fully integrated CDMO.
Before joining Ajinomoto, Mr. Enloe served as head of Lonza’s Viral Therapeutics business unit, which was the result of Lonza’s acquisition of Vivante GMP Solutions, a gene therapy CDMO that he founded in June 2009 and where he served as president and CEO until its sale to Lonza AG. Under Mr. Enloe’s leadership, the business experienced rapid expansion, with revenues increasing 500% over three years.
Preceding Vivante, Mr. Enloe spent 14 years with the biotech company, Introgen Therapeutics, joining as its first employee in 1995 and serving as senior vice president and COO before being named president and CEO. Mr. Enloe served an integral role in taking the company through a successful IPO in 2020, as well as several other significant financial transactions. In addition, he oversaw multiple large corporate and academic collaborations, as well as the filing of license applications with both the FDA and European regulatory authorities for Introgen’s lead product.
Mr. Enloe received a Bachelor of Business Administration in Accounting from the University of Texas at Austin. He is a Certified Public Accountant and started his career in public accounting with Arthur Andersen & Co.